Cadila Pharmaceuticals and Wellesta Holdings Pte. Ltd. have signed a Memorandum of Understanding (MoU) to establish a strategic joint venture aimed at expanding access to high-quality pharmaceutical and healthcare solutions across South-East Asia and selected international markets.

The partnership will leverage Cadila Pharmaceuticals' strengths in research and development, manufacturing, regulatory compliance, and its broad portfolio of prescription medicines, consumer healthcare products, and specialty therapies. 

Wellesta Holdings will contribute its established commercialization infrastructure, regulatory expertise, market access capabilities, distribution network, and commercial presence across South-East Asia and other international markets.

The proposed joint venture will focus on identifying, developing, and commercializing high-potential pharmaceutical and healthcare products by combining Cadila’s innovation and manufacturing capabilities with Wellesta’s regional market expertise. 

The collaboration is expected to strengthen Cadila’s footprint in key growth markets while expanding Wellesta’s portfolio with differentiated healthcare offerings.

Beyond South-East Asia, the joint venture is envisioned as a long-term growth platform targeting expansion across the Middle East, Africa, and other emerging markets. 

Both companies said the collaboration reflects their shared commitment to improving healthcare access through innovation, quality, and strong commercial execution while creating long-term value for patients, healthcare professionals, and stakeholders.